Aim Immunotech Inc (AIM)

$2.61 -0.09 (-3.33%)
Market Cap 7.31M
Revenue (ttm) 170,000.00
Net Income (ttm) -17.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,188.24%
Debt to Equity Ratio 0.00
Volume 34,601
Avg Vol 196,724
Day's Range N/A - N/A
Shares Out 2.71M
Stochastic %K 88%
Beta 0.88
Analysts Sell
Price Target $150.00

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 352 448 7797
Fax: 352 480 4620
Address:
2117 SW Highway 484, Ocala, United States
longzone
longzone Aug. 25 at 3:27 PM
$QH come to $AIM
0 · Reply
longzone
longzone Aug. 25 at 2:47 PM
$AIM
0 · Reply
T2HeadedEagle
T2HeadedEagle Aug. 25 at 2:21 PM
$AIM is this really going to $2 before it shoots up?
1 · Reply
h2oMark
h2oMark Aug. 25 at 12:47 AM
$AIM As just an inkling of speculative optimism, I'll share a thought - in the past, typically whenever the sp has reached a new all time low, Tom has purchased a handful of shares. So if the current $2.70ish holds, and last weeks' $2.40ish was a new ATL, & Tom didn't make a purchase, it m a y be because something is about to pop. I know ... I'm grasping at straws
2 · Reply
brandonscience
brandonscience Aug. 24 at 4:31 AM
$AIM Ampligen activates TLR3, boosts interferons, dendritic cells, NK and T cells; Imfinzi blocks PD-L1, keeps T cells active. Pancreatic cancer usually resists checkpoints due to immunosuppressive microenvironment; combo turns cold tumors hot, more T cells for Imfinzi, stronger anti-tumor effect. MoA is clear and well supported. Leadership has historically gotten in the way, but $AZN may help them finally reach a phase 3 and show what ampligen can really do.
1 · Reply
T2HeadedEagle
T2HeadedEagle Aug. 22 at 8:00 PM
$AIM now that I sold this will shoot up like a 🚀
5 · Reply
Paristommy
Paristommy Aug. 22 at 6:50 PM
$AIM Wow, the POS stole everybody s money , now he’s on the corner begging!!!Dont be surprised if he takes what lil us longs have left with another R/S.
0 · Reply
deesht
deesht Aug. 22 at 6:29 PM
$AIM What did CEO do for decades? Dancing on only one drug name. The previous ticker was $HEB. From that time so many Stocktwits members warned against CEO's cheat, but I ignored and bought stocks relying on CEO's false narations. Now I am trying to alert to newbies. As soon as stock moves a little, CEO hits with dilution. If their drug is so useful why can't they bring fiancés??
1 · Reply
longzone
longzone Aug. 22 at 5:30 PM
$AIM this goes up fast!!! Just need more volume
1 · Reply
T2HeadedEagle
T2HeadedEagle Aug. 22 at 3:45 PM
$AIM I sold for now with very little profit, CEO is sounding a little desperate. I will keep an eye on it and most likely will buy in again but for now will keep a close eye on.
2 · Reply
Latest News on AIM
AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Aug 21, 2025, 9:00 AM EDT - 4 days ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 15, 2025, 9:00 AM EDT - 10 days ago

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 8:55 AM EDT - 11 days ago

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

Aug 6, 2025, 9:00 AM EDT - 19 days ago

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Aug 4, 2025, 9:00 AM EDT - 21 days ago

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Why Is Micro-Cap AIM ImmunoTech Stock Surging?

Jul 28, 2025, 11:12 AM EDT - 4 weeks ago

Why Is Micro-Cap AIM ImmunoTech Stock Surging?

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

Jul 2, 2025, 8:55 AM EDT - 7 weeks ago

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

Jun 20, 2025, 4:15 PM EDT - 2 months ago

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

AIM ImmunoTech Resumes Trading on NYSE American

Jun 17, 2025, 8:55 AM EDT - 2 months ago

AIM ImmunoTech Resumes Trading on NYSE American

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Jun 12, 2025, 8:30 AM EDT - 2 months ago

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

Jun 12, 2025, 8:00 AM EDT - 2 months ago

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Jun 11, 2025, 4:15 PM EDT - 2 months ago

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript

May 13, 2025, 9:54 AM EDT - 3 months ago

Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

May 8, 2025, 8:45 AM EDT - 3 months ago

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

Apr 7, 2025, 1:26 PM EDT - 5 months ago

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

Apr 4, 2025, 4:45 PM EDT - 5 months ago

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)

Apr 4, 2025, 4:05 PM EDT - 5 months ago

NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)

AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript

Apr 1, 2025, 9:19 AM EDT - 5 months ago

AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript

Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript

Mar 28, 2025, 11:39 AM EDT - 5 months ago

Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Mar 11, 2025, 8:45 AM EDT - 5 months ago

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

Feb 28, 2025, 8:45 AM EST - 6 months ago

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Feb 26, 2025, 1:20 PM EST - 6 months ago

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

Feb 26, 2025, 8:30 AM EST - 6 months ago

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

Feb 25, 2025, 8:30 AM EST - 6 months ago

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

Feb 11, 2025, 8:45 AM EST - 6 months ago

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

Feb 11, 2025, 8:30 AM EST - 6 months ago

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks

Feb 7, 2025, 8:50 AM EST - 7 months ago

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions

Jan 23, 2025, 8:50 AM EST - 7 months ago

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS

Jan 22, 2025, 8:30 AM EST - 7 months ago

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones

Jan 15, 2025, 9:05 AM EST - 7 months ago

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Dec 17, 2024, 4:45 PM EST - 8 months ago

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

Dec 17, 2024, 3:10 PM EST - 8 months ago

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card

Dec 16, 2024, 8:00 AM EST - 9 months ago

AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card

Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board

Dec 14, 2024, 4:54 PM EST - 9 months ago

Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members

Dec 12, 2024, 3:00 PM EST - 9 months ago

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

Dec 12, 2024, 9:00 AM EST - 9 months ago

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

Kellner Group Announces Support from Another Former AIM Senior Executive

Dec 12, 2024, 8:16 AM EST - 9 months ago

Kellner Group Announces Support from Another Former AIM Senior Executive

AIM's Clinical Strategy Under Incumbent Board Has Totally Failed

Dec 11, 2024, 7:30 AM EST - 9 months ago

AIM's Clinical Strategy Under Incumbent Board Has Totally Failed

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K.

Dec 10, 2024, 10:20 AM EST - 9 months ago

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K.

Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected

Dec 10, 2024, 7:30 AM EST - 9 months ago

Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected

AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment

Dec 6, 2024, 9:15 AM EST - 9 months ago

AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment

Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card

Dec 6, 2024, 8:34 AM EST - 9 months ago

Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card

ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M.

Dec 5, 2024, 9:00 AM EST - 9 months ago

ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M.

AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group's Nominees to the Board

Dec 2, 2024, 8:00 AM EST - 9 months ago

AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group's Nominees to the Board

AIM ImmunoTech Refutes Activist Group's False and Misleading Claims

Nov 27, 2024, 3:30 PM EST - 9 months ago

AIM ImmunoTech Refutes Activist Group's False and Misleading Claims

AIM ImmunoTech Announces Cash Conservation Plan

Nov 27, 2024, 8:00 AM EST - 9 months ago

AIM ImmunoTech Announces Cash Conservation Plan

AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders

Nov 25, 2024, 8:00 AM EST - 9 months ago

AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders

AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer

Nov 19, 2024, 8:00 AM EST - 9 months ago

AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer

AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript

Nov 15, 2024, 10:32 AM EST - 10 months ago

AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 15, 2024, 7:29 AM EST - 10 months ago

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

longzone
longzone Aug. 25 at 3:27 PM
$QH come to $AIM
0 · Reply
longzone
longzone Aug. 25 at 2:47 PM
$AIM
0 · Reply
T2HeadedEagle
T2HeadedEagle Aug. 25 at 2:21 PM
$AIM is this really going to $2 before it shoots up?
1 · Reply
h2oMark
h2oMark Aug. 25 at 12:47 AM
$AIM As just an inkling of speculative optimism, I'll share a thought - in the past, typically whenever the sp has reached a new all time low, Tom has purchased a handful of shares. So if the current $2.70ish holds, and last weeks' $2.40ish was a new ATL, & Tom didn't make a purchase, it m a y be because something is about to pop. I know ... I'm grasping at straws
2 · Reply
brandonscience
brandonscience Aug. 24 at 4:31 AM
$AIM Ampligen activates TLR3, boosts interferons, dendritic cells, NK and T cells; Imfinzi blocks PD-L1, keeps T cells active. Pancreatic cancer usually resists checkpoints due to immunosuppressive microenvironment; combo turns cold tumors hot, more T cells for Imfinzi, stronger anti-tumor effect. MoA is clear and well supported. Leadership has historically gotten in the way, but $AZN may help them finally reach a phase 3 and show what ampligen can really do.
1 · Reply
T2HeadedEagle
T2HeadedEagle Aug. 22 at 8:00 PM
$AIM now that I sold this will shoot up like a 🚀
5 · Reply
Paristommy
Paristommy Aug. 22 at 6:50 PM
$AIM Wow, the POS stole everybody s money , now he’s on the corner begging!!!Dont be surprised if he takes what lil us longs have left with another R/S.
0 · Reply
deesht
deesht Aug. 22 at 6:29 PM
$AIM What did CEO do for decades? Dancing on only one drug name. The previous ticker was $HEB. From that time so many Stocktwits members warned against CEO's cheat, but I ignored and bought stocks relying on CEO's false narations. Now I am trying to alert to newbies. As soon as stock moves a little, CEO hits with dilution. If their drug is so useful why can't they bring fiancés??
1 · Reply
longzone
longzone Aug. 22 at 5:30 PM
$AIM this goes up fast!!! Just need more volume
1 · Reply
T2HeadedEagle
T2HeadedEagle Aug. 22 at 3:45 PM
$AIM I sold for now with very little profit, CEO is sounding a little desperate. I will keep an eye on it and most likely will buy in again but for now will keep a close eye on.
2 · Reply
ehschunk
ehschunk Aug. 22 at 3:17 PM
$AIM I dont know who this quote is attributable to, Mark Twain or George Carlin...I dont argue with idiots. I find they bring you down to their level and beat with you experience...
0 · Reply
rayk1
rayk1 Aug. 22 at 3:16 PM
$AIM is “Mr. 2 Cents/share” now begging for collaboration? Awkward… please Equels….GO!!!
4 · Reply
crown88
crown88 Aug. 22 at 2:54 PM
$AIM is this stock dead?
3 · Reply
longzone
longzone Aug. 22 at 2:51 PM
$AIM why there is no volume?
0 · Reply
Cantstandzya
Cantstandzya Aug. 22 at 1:01 PM
$AIM shorts quietly covering . Except for Kermit . He's taking a bath .
1 · Reply
deesht
deesht Aug. 22 at 12:38 PM
$AIM Check the history of this CEO, he and executives are getting exorbitantly high celeries v/s stock performance. They should not be getting any $, from shareholders pocket. For decades this loot is going on. Check $VXRT, shareholders are strongly united and not allowing them rs as they tried to cheat holders.
0 · Reply
RRRJJJ
RRRJJJ Aug. 22 at 6:33 AM
$AIM Ya’ll been warned, hit the eject button on this…Downward spiral since 2000 with no upcoming pr… Peep the chart…
4 · Reply
brandonscience
brandonscience Aug. 22 at 12:36 AM
$RNXT $AIM My RNXT folks, AIM’s had a rocky (and very storied) past with money troubles, management stumbles, and FDA rejections, but ampligen is a real deal biologic and its latest pancreatic cancer results with AstraZeneca’s Imfinzi finally give it a real shot at a big Phase 3 trial, which is what they have always needed. Do your DD but if youre ever getting in, now might be the time.
4 · Reply
T2HeadedEagle
T2HeadedEagle Aug. 21 at 10:49 PM
$AIM $8 - $12 range coming up and then hopefully much higher. Let’s goooooo 🔥🔥
1 · Reply
ehschunk
ehschunk Aug. 21 at 4:21 PM
$AIM The night is always darkest right before dawn. Let's see if AIM can move steadily up now.
0 · Reply
T2HeadedEagle
T2HeadedEagle Aug. 21 at 3:37 PM
$AIM up to $8 then we see if it comes back down or not. Ride the 🚂
0 · Reply
Paristommy
Paristommy Aug. 21 at 3:25 PM
$AIM @uuddlrlr Why are showing this weasel any respect, think about it updated in 6 months, which brings us to the next BOD elections !!The old saying in life , I wish I knew then , what I know now !!This POS makes me Sick !!!
1 · Reply